The trajectory of companies tied to Sildenafil's past presents a challenging investment landscape. While the initial surge generated substantial returns website , generic alternatives have significantly impacted revenue. Investing in associated pharmaceutical firms now requires a careful assessment of intellectual property rights , evolving healthc